Sickle Cell Anemia
Conditions
Keywords
Sickle cell anemia
Brief summary
This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.
Interventions
None listed
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype 2. Patients ≥ 16 years of age 3. Patients with ≥ 6 months of follow-up data available from first SCD treatment at the center after they reach 16 years old 4. At least one SF reading during a non-acute phase on or after the first SCD treatment at the center after they reach 16 years old
Exclusion criteria
1. Patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for SCD (1) within the six months before the index date or (2) during the patient observation period 2. Patients with sickle cell trait Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sickle cell complications | average of 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Utilization of health care delivery to treat sickle cell complications | average of 5 years |
| Overall survival | average of 5 years |
| Utilization of blood transfusions (patients with frequent transfusions only) | average of 5 years |
| Burden of iron overload (patients with frequent transfusions only) | average of 5 years |
| Utilization of Iron Chelation Therapies (ICTs) (patients receiving deferoxamine or deferasirox [Exjade®] only) | average of 5 years |
Countries
United States
Outcome results
None listed